Intravitreal dexamethasone implant Ozurdex in the treatment of diabetic macular edema in patients not previously treated with any intravitreal drug: a prospective 12-month follow-up study
Autor: | Víctor Menezo, Marc Menezo, Manuel Roca, Isabel Pascual |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
Drug medicine.medical_specialty genetic structures media_common.quotation_subject Diabetic macular edema Visual Acuity dexamethasone 030204 cardiovascular system & hematology Dexamethasone Macular Edema 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Ophthalmology medicine Humans In patient Prospective Studies 030212 general & internal medicine Glucocorticoids Aged media_common Drug Implants Diabetic Retinopathy business.industry Diabetes General Medicine Middle Aged medicine.disease eye diseases Treatment Outcome Ozurdex Intravitreal Injections Female Implant intravitreal implant business Previously treated diabetic macular edema Follow-Up Studies medicine.drug Month follow up |
Zdroj: | CURRENT MEDICAL RESEARCH AND OPINION r-FISABIO. Repositorio Institucional de Producción Científica instname r-FISABIO: Repositorio Institucional de Producción Científica Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
ISSN: | 0300-7995 |
Popis: | Objective: To evaluate the mid-long-term efficacy and safety of the dexamethasone intravitreal (DEX) implant (Ozurdex(1)) in naive patients with diabetic macular edema (DME). Methods: Prospective and single-center study conducted on consecutive patients with a diagnosis of DME, who received a DEX implant and were followed up for at least 12 months. The main outcomes measurements were the mean change in best corrected visual acuity (BCVA) and in foveal thickness (FT) as compared to the baseline values. Results: Of the 84 screened patients 50 were included in the study. The BCVA significantly improved from 52.4 (20.4) letters at baseline to 62.6 (15.6), 61.2 (18.4), 61.6 (18.6), 60.6 (19.0), and 60.6 (18.8) at 2, 4, 6, 12 months and end of follow-up period, respectively (repeated measures ANOVA and the Greenhouse-Geisser correction; p = .0008). At the end of the follow-up period, a gain of BCVA of >= 5, >= 10, and >= 15 letters were observed in 26 (52.0%), 18 (36.0%), and 16 (32.0%) patients, respectively. The mean FT was significantly reduced from 446.0 (139.9) mu m at baseline to 327.2 (103.6) at the end of follow-up (repeated measures ANOVA and the Greenhouse-Geisser correction; p = .0008). During the study follow-up, the patients receive a mean of 3.4 (2.9-3.9) implants. Of the 32 phakic eyes at baseline, 17 (53.1%) either developed new lens opacity or progression of an existing opacity. Conclusion: In eyes with DME not previously treated with intravitreal drugs, DEX implants provide meaningful functional and anatomical benefits, and these results are sustained mid-long-term. |
Databáze: | OpenAIRE |
Externí odkaz: |